The institutional, research, and commercial entities that constitute the discipline's operating infrastructure.
The discipline's operating infrastructure is organized around four functional roles: the founding institutional entity, opticeutical operations, endoceutical operations, and research affiliates.
The canonical reference at endogenicpharmacology.com is published by the founding entity and is independent of the operating affiliates' commercial activities. Affiliates are listed here for institutional transparency, not as endorsement of any specific product line.
Founding institutional entity behind endogenicpharmacology.com. Holds the proprietary technology base — the Ac-X-NH2 dual-terminus modification, the eleven-application provisional patent portfolio filed March 2026, and the institutional research and licensing infrastructure. The canonical reference at this site is published by Atumnus, Inc.
Operating affiliates in the opticeutical (over-the-counter) tier translate bioregulator compositions into consumer-accessible product formats — topical creams and serums, transdermal patches, intranasal sprays, sublingual films, and oral preparations. Operations are governed by the regulatory pathways appropriate to each format (cosmetic, dietary supplement, OTC monograph).
Operating affiliates in the endoceutical (prescription) tier translate bioregulator compositions into clinically supervised therapeutic preparations — including 503A pharmacy-compounded preparations and FDA-pathway preparations. Affiliates include licensed compounding pharmacies, clinical-trial sponsors, and indication-development partners.
Synthesis, biochemistry, and clinical-research affiliates support the discipline's ongoing scientific program — peptide synthesis at clinical and commercial scale, indication-specific in-vivo and clinical-observational study, and the maintenance of the working bibliography. Research affiliations are coordinated through the institutional Contact for Researchers pathway.